First gene therapy for children with metachromatic leukodystrophy approved by FDA

The U.S. Food and Drug Administration has approved Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) as the first gene therapy for the treatment of children with metachromatic leukodystrophy (MLD).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup